contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


correction-issue-and-re-purchase-of-class-c-shares-for-shareholder-program

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.

Oncopeptides

Clarficiation in third paragraph (in bold)Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused...

<div class="mfn-correction"><p>Clarficiation in third paragraph (in bold)</p></div><div class="mfn-preamble"><p><strong>Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares.</strong></p></div><div class="mfn-body"><p>The shares are issued and re-purchased in accordance with the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024, which were adopted by the Annual General Meetings 2022 and 2024, respectively, as well as other outstanding shareholder programs for members of the Board of Directors (the “Incentive Programs”).</p><p>DNB Bank ASA, Sweden Branch will subscribe for the entire issue of new class C shares at a subscription price of approximately SEK 0.11 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors’ resolution, be re-purchased <strong>by Oncopeptides</strong> for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of the Incentive Programs.</p><p>The purpose of the re-purchase is to ensure delivery of shares in accordance with the Incentive Programs as well as to cover any social costs due to Co-worker LTIP 2022 and Co-worker LTIP 2024. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.</p></div><div class="mfn-footer mfn-contacts mfn-ad2e6a7e9211"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)<br>E-mail: <a rel="noopener" href="mailto:david.augustsson@oncopeptides.com">david.augustsson@oncopeptides.com</a><br>Cell phone: +46 76 229 38 68</p></div><div class="mfn-footer mfn-about mfn-05abf943815f"><p><strong class="mfn-heading-1">About Oncopeptides</strong><br>Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.&nbsp;</p><p>The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.&nbsp;Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.</p><p>Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.</p><p>The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed&nbsp;on Nasdaq Stockholm with the ticker ONCO.</p><p>For more information see:&nbsp;<a rel="noopener" href="http://www.oncopeptides.com/en">www.oncopeptides.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-02-28 07:00 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/d19872eb-4eb7-47bf-b981-4ec7a805f219/issue-and-re-purchase-of-class-c-shares-for-shareholder-program.pdf" class="mfn-generated mfn-primary">Issue and re-purchase of class C shares for shareholder program</a></p></div>